Mylan NV (MYL) - Medical Equipment - Deals and Alliances Profile
- GDME31565D
- Pages: 66
- October 2018
- Total Views:1135
- Region : Europe
- GlobalData
- Equity Research Report
Details
Summary
Mylan NV (Mylan) is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generics and branded medicines, and consumer healthcare products. It offers pharmaceutical products in multiple forms for various disease conditions related to respiratory and allergy, cardiovascular, dermatology, central nervous system (CNS) and cancer, besides anti-rretrovirals, anaphylaxis products and others. The company also offers active pharmaceutical ingredients (APIs). The company sells its products to retail pharmacy chains, wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies. The company markets its products in various countries worldwide. Mylan is headquartered in Hatfield, Hertfordshire, the UK.
Mylan NV (MYL)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Mylan NV, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Mylan NV, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Mylan NV, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Mylan NV, Medical Equipment, Deals By Market, 2012 to YTD 2018 9
Mylan NV, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Mylan NV, Medical Equipment, Deal Details 11
Venture Financing 11
Zyomyx Raises USD 6 Million In First Closing Of Series 2 Preferred Financing 11
Partnerships 12
Mylan Teoranta Enters into Licensing Agreement with Contura 12
Mylan Enters into Partnership with Atomo Diagnostics 13
Mylan Enters Into Distribution Agreement With Zyomyx For CD4 T-Cell Count Test 14
Phosphagenics Enters Into Licensing Agreement With Agila Specialties For TPM Technology 16
Mylan Specialty Enters Into Licensing Agreement With Pfizer For EpiPen 17
Debt Offering 18
Mylan Prices Private Placement of 5.2% Notes Due 2048 for USD750 Million 18
Mylan Prices Private Placement of 4.55% Notes Due 2028 for USD750 Million 19
Mylan Raises USD551.6 Million in Public Offering of Bonds Due 2020 20
Mylan Raises USD1 Billion in Private Placement of 5.25% Notes Due 2046 21
Mylan Raises USD2.25 Billion in Private Placement of 3.95% Notes Due 2026 22
Mylan Raises USD1 Billion in Private Placement of 2.5% Notes Due 2019 23
Mylan Raises USD2.25 Billion in Private Placement of 3.15% Notes Due 2021 24
Acquisition 25
Mylan Acquires Meda for USD9.42 Billion 25
Mylan NV-Key Competitors 27
Mylan NV-Key Employees 28
Mylan NV-Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 36
Strategy And Business Planning 36
Sep 25, 2018: Mylan signs HIV test commercialisation deal with Atomo Diagnostics 36
Financial Announcements 37
Aug 08, 2018: Mylan reports second quarter 2018 results and updates 2018 guidance 37
May 09, 2018: Mylan Reports First Quarter 2018 Results and Reaffirms 2018 Guidance 42
Feb 28, 2018: Mylan Reports Full Year and Fourth Quarter 2017 Results and Provides 2018 Guidance 44
Nov 06, 2017: Mylan Reports Third Quarter 2017 Results and Updates 2017 Guidance 46
Aug 09, 2017: Mylan Reports Second Quarter 2017 Results and Updates 2017 Guidance 48
May 10, 2017: Mylan Reports First Quarter 2017 Results 52
Mar 01, 2017: Mylan Reports Fourth Quarter and Full Year 2016 Results and Provides 2017 Guidance 54
Corporate Communications 56
May 14, 2018: Mylan and West Virginia University Join Forces to Inspire West Virginia Youth Through STEM-CARE 56
Feb 26, 2018: 16-Year Veteran Director Wendy Cameron to Retire from Mylan Board after 2018 AGM 58
Sep 13, 2017: Mylan Names Dennis Zeleny as Chief Human Relations Officer 59
May 01, 2017: Mylan Nominates Sjoerd Vollebregt for Election to Board of Directors 60
Mar 28, 2017: Mylan Names Former SEC Commissioner Daniel Gallagher as Chief Legal Officer 61
Legal and Regulatory 62
Jun 28, 2018: Mylan Statement: Morgantown Operations 62
Nov 10, 2017: Mylan Announces Voluntary Delisting from the Tel Aviv Stock Exchange 63
Oct 31, 2017: Mylan Provides Statement in Response to Announcement of Proposed Amendments to Civil Complaint 64
Product News 65
Apr 11, 2018: Investor Day Highlights Durability of Mylan's Global Platform 65
Appendix 66
Methodology 66
About GlobalData 66
Contact Us 66
Disclaimer 66
List Of Figure
List of Figures
Mylan NV, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Mylan NV, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Mylan NV, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Mylan NV, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Mylan NV, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Mylan NV, Medical Equipment, Deals by Type, 2012 to YTD 2018 7
Mylan NV, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Mylan NV, Medical Equipment, Deals by Market, 2012 to YTD 2018 9
List Of Table
List of Tables
Mylan NV, Medical Equipment, Key Facts, 2017 2
Mylan NV, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Mylan NV, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Mylan NV, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Mylan NV, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Mylan NV, Deals By Market, 2012 to YTD 2018 9
Mylan NV, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Zyomyx Raises USD 6 Million In First Closing Of Series 2 Preferred Financing 11
Mylan Teoranta Enters into Licensing Agreement with Contura 12
Mylan Enters into Partnership with Atomo Diagnostics 13
Mylan Enters Into Distribution Agreement With Zyomyx For CD4 T-Cell Count Test 14
Phosphagenics Enters Into Licensing Agreement With Agila Specialties For TPM Technology 16
Mylan Specialty Enters Into Licensing Agreement With Pfizer For EpiPen 17
Mylan Prices Private Placement of 5.2% Notes Due 2048 for USD750 Million 18
Mylan Prices Private Placement of 4.55% Notes Due 2028 for USD750 Million 19
Mylan Raises USD551.6 Million in Public Offering of Bonds Due 2020 20
Mylan Raises USD1 Billion in Private Placement of 5.25% Notes Due 2046 21
Mylan Raises USD2.25 Billion in Private Placement of 3.95% Notes Due 2026 22
Mylan Raises USD1 Billion in Private Placement of 2.5% Notes Due 2019 23
Mylan Raises USD2.25 Billion in Private Placement of 3.15% Notes Due 2021 24
Mylan Acquires Meda for USD9.42 Billion 25
Mylan NV, Key Competitors 27
Mylan NV, Key Employees 28
Mylan NV, Other Locations 29
Mylan NV, Subsidiaries 30
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
Mylan NV, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Company Profile
Company Profile Title
Summary
Mylan NV (Mylan) is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generics and branded medicines, and consumer healthcare products. It offers pharmaceutical products in multiple forms for various disease conditions related to respiratory and allergy, cardiovascular, dermatology, central nervous system (CNS) and cancer, besides anti-rretrovirals, anaphylaxis products and others. The company also offers active pharmaceutical ingredients (APIs). The company sells its products to retail pharmacy chains, wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies. The company markets its products in various countries worldwide. Mylan is headquartered in Hatfield, Hertfordshire, the UK.
Mylan NV (MYL)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Mylan NV, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Mylan NV, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Mylan NV, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Mylan NV, Medical Equipment, Deals By Market, 2012 to YTD 2018 9
Mylan NV, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Mylan NV, Medical Equipment, Deal Details 11
Venture Financing 11
Zyomyx Raises USD 6 Million In First Closing Of Series 2 Preferred Financing 11
Partnerships 12
Mylan Teoranta Enters into Licensing Agreement with Contura 12
Mylan Enters into Partnership with Atomo Diagnostics 13
Mylan Enters Into Distribution Agreement With Zyomyx For CD4 T-Cell Count Test 14
Phosphagenics Enters Into Licensing Agreement With Agila Specialties For TPM Technology 16
Mylan Specialty Enters Into Licensing Agreement With Pfizer For EpiPen 17
Debt Offering 18
Mylan Prices Private Placement of 5.2% Notes Due 2048 for USD750 Million 18
Mylan Prices Private Placement of 4.55% Notes Due 2028 for USD750 Million 19
Mylan Raises USD551.6 Million in Public Offering of Bonds Due 2020 20
Mylan Raises USD1 Billion in Private Placement of 5.25% Notes Due 2046 21
Mylan Raises USD2.25 Billion in Private Placement of 3.95% Notes Due 2026 22
Mylan Raises USD1 Billion in Private Placement of 2.5% Notes Due 2019 23
Mylan Raises USD2.25 Billion in Private Placement of 3.15% Notes Due 2021 24
Acquisition 25
Mylan Acquires Meda for USD9.42 Billion 25
Mylan NV-Key Competitors 27
Mylan NV-Key Employees 28
Mylan NV-Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 36
Strategy And Business Planning 36
Sep 25, 2018: Mylan signs HIV test commercialisation deal with Atomo Diagnostics 36
Financial Announcements 37
Aug 08, 2018: Mylan reports second quarter 2018 results and updates 2018 guidance 37
May 09, 2018: Mylan Reports First Quarter 2018 Results and Reaffirms 2018 Guidance 42
Feb 28, 2018: Mylan Reports Full Year and Fourth Quarter 2017 Results and Provides 2018 Guidance 44
Nov 06, 2017: Mylan Reports Third Quarter 2017 Results and Updates 2017 Guidance 46
Aug 09, 2017: Mylan Reports Second Quarter 2017 Results and Updates 2017 Guidance 48
May 10, 2017: Mylan Reports First Quarter 2017 Results 52
Mar 01, 2017: Mylan Reports Fourth Quarter and Full Year 2016 Results and Provides 2017 Guidance 54
Corporate Communications 56
May 14, 2018: Mylan and West Virginia University Join Forces to Inspire West Virginia Youth Through STEM-CARE 56
Feb 26, 2018: 16-Year Veteran Director Wendy Cameron to Retire from Mylan Board after 2018 AGM 58
Sep 13, 2017: Mylan Names Dennis Zeleny as Chief Human Relations Officer 59
May 01, 2017: Mylan Nominates Sjoerd Vollebregt for Election to Board of Directors 60
Mar 28, 2017: Mylan Names Former SEC Commissioner Daniel Gallagher as Chief Legal Officer 61
Legal and Regulatory 62
Jun 28, 2018: Mylan Statement: Morgantown Operations 62
Nov 10, 2017: Mylan Announces Voluntary Delisting from the Tel Aviv Stock Exchange 63
Oct 31, 2017: Mylan Provides Statement in Response to Announcement of Proposed Amendments to Civil Complaint 64
Product News 65
Apr 11, 2018: Investor Day Highlights Durability of Mylan's Global Platform 65
Appendix 66
Methodology 66
About GlobalData 66
Contact Us 66
Disclaimer 66
List Of Figure
List of Figures
Mylan NV, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Mylan NV, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Mylan NV, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Mylan NV, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Mylan NV, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Mylan NV, Medical Equipment, Deals by Type, 2012 to YTD 2018 7
Mylan NV, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Mylan NV, Medical Equipment, Deals by Market, 2012 to YTD 2018 9
List Of Table
List of Tables
Mylan NV, Medical Equipment, Key Facts, 2017 2
Mylan NV, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Mylan NV, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Mylan NV, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Mylan NV, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Mylan NV, Deals By Market, 2012 to YTD 2018 9
Mylan NV, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Zyomyx Raises USD 6 Million In First Closing Of Series 2 Preferred Financing 11
Mylan Teoranta Enters into Licensing Agreement with Contura 12
Mylan Enters into Partnership with Atomo Diagnostics 13
Mylan Enters Into Distribution Agreement With Zyomyx For CD4 T-Cell Count Test 14
Phosphagenics Enters Into Licensing Agreement With Agila Specialties For TPM Technology 16
Mylan Specialty Enters Into Licensing Agreement With Pfizer For EpiPen 17
Mylan Prices Private Placement of 5.2% Notes Due 2048 for USD750 Million 18
Mylan Prices Private Placement of 4.55% Notes Due 2028 for USD750 Million 19
Mylan Raises USD551.6 Million in Public Offering of Bonds Due 2020 20
Mylan Raises USD1 Billion in Private Placement of 5.25% Notes Due 2046 21
Mylan Raises USD2.25 Billion in Private Placement of 3.95% Notes Due 2026 22
Mylan Raises USD1 Billion in Private Placement of 2.5% Notes Due 2019 23
Mylan Raises USD2.25 Billion in Private Placement of 3.15% Notes Due 2021 24
Mylan Acquires Meda for USD9.42 Billion 25
Mylan NV, Key Competitors 27
Mylan NV, Key Employees 28
Mylan NV, Other Locations 29
Mylan NV, Subsidiaries 30
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
Mylan NV, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Ask A Question
Our Team Will Assist You in What You Are Looking For
or 
: +91 98100 26150
: ankurgupta1984
Related Reports
Page 179 | 
February 2020
Page 116 | January 2020
Page 235 | January 2020
Page 183 | September 2019
Page 244 | August 2019